Apr 6, 2021 at 6:20AM Follow @jimhalley
Johnson & Johnson (NYSE:JNJ) is the very definition of a value stock: five consecutive years of annual revenue growth, an above-average dividend that has been raised for 58 consecutive years in a row, and a diversified product portfolio capable of weathering various lawsuits, pandemics, and whatever else gets thrown its way.
Last week, it was reported that a batch of 15 million doses of the company s vaccine that was being made for Johnson & Johnson by
Emergent BioSolutions (NYSE:EBS) had to be thrown out because a mistake had been made regarding one of the batch s ingredients. Emergent s stock dropped on the news; J&J stock didn t. Now, Johnson & Johnson has been directed by the U.S. government to take over vaccine operations at the facility.
Author Bio
Reuben Gregg Brewer believes dividends are a window into a company s soul. He tries to invest in good souls.
The stock market is usually pretty good at discounting the future, but sometimes investors get a little too pessimistic. That appears to be what is going on at global industrial giant
Here s a quick look at why long-term investors might want to put this stock on their wish lists anyway.
A valuable opportunity
Shares of 3M are about breakeven for the year, which is actually not so bad given the coronavirus pandemic. That said, the
SPDR S&P 500 ETF as a proxy, is up around 15%, so 3M is actually lagging well behind the broader market. Push back a little bit further and 3M s stock performance is actually pretty grim, with shares down roughly 25% over the last three years, compared to a 37% gain for the S&P 500.